Hotta K - Search Results

1

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Among authors: hotta k. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.

2

Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer.

Kusaba H, Tamura T, Shimoyama T, Hotta K, Inoue A, Nokihara H, Ueda Y, Akiyama Y, Yamamoto N, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N. Kusaba H, et al. Among authors: hotta k. Jpn J Clin Oncol. 2002 Feb;32(2):43-7. doi: 10.1093/jjco/hyf013. Jpn J Clin Oncol. 2002. PMID: 11948227 Clinical Trial.

3

Successful treatment of limited disease-small cell lung cancer with multimodality treatment consisting of concurrent chemoradiotherapy, high-dose chemotherapy with autologous peripheral blood stem cell transplantation and surgical resection.

Hotta K, Ueoka H, Kiura K, Tabata M, Kondoh E, Segawa Y, Date H, Shimizu N, Yoshino T, Harada M, Tanimoto M. Hotta K, et al. Intern Med. 2003 Dec;42(12):1223-7. doi: 10.2169/internalmedicine.42.1223. Intern Med. 2003. PMID: 14714964 Free article.

4

Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.

Watanabe H, Yamamoto N, Tamura T, Shimoyama T, Hotta K, Inoue A, Sawada M, Akiyama Y, Kusaba H, Nokihara H, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N. Watanabe H, et al. Among authors: hotta k. Jpn J Clin Oncol. 2003 Dec;33(12):626-30. doi: 10.1093/jjco/hyg116. Jpn J Clin Oncol. 2003. PMID: 14769840

5

Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer.

Hotta K, Takigawa N, Kiura K, Tabata M, Umemura S, Ogino A, Uchida A, Bessho A, Segawa Y, Shinkai T, Nogami N, Harita S, Okimoto N, Ueoka H, Tanimoto M. Hotta K, et al. Anticancer Res. 2005 May-Jun;25(3c):2429-34. Anticancer Res. 2005. PMID: 16080470 Free article. Clinical Trial.

6

Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.

Hotta K, Fujiwara Y, Matsuo K, Suzuki T, Kiura K, Tabata M, Takigawa N, Ueoka H, Tanimoto M. Hotta K, et al. Cancer. 2007 Mar 1;109(5):939-48. doi: 10.1002/cncr.22478. Cancer. 2007. PMID: 17285602 Free article.

7

A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.

Tabata M, Kiura K, Okimoto N, Segawa Y, Shinkai T, Yonei T, Kuyama S, Harita S, Hotta K, Ueoka H, Tanimoto M. Tabata M, et al. Among authors: hotta k. Cancer Chemother Pharmacol. 2007 Jun;60(1):1-6. doi: 10.1007/s00280-006-0336-0. Epub 2007 Mar 29. Cancer Chemother Pharmacol. 2007. PMID: 17393168 Clinical Trial.

8

Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials.

Hotta K, Fujiwara Y, Kiura K, Takigawa N, Tabata M, Ueoka H, Tanimoto M. Hotta K, et al. J Thorac Oncol. 2007 May;2(5):402-7. doi: 10.1097/01.JTO.0000268673.95119.c7. J Thorac Oncol. 2007. PMID: 17473655 Free article.

9

Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer.

Kuyama S, Hotta K, Tabata M, Segawa Y, Fujiwara Y, Takigawa N, Kiura K, Ueoka H, Eguchi K, Tanimoto M. Kuyama S, et al. Among authors: hotta k. J Thorac Oncol. 2008 May;3(5):477-82. doi: 10.1097/JTO.0b013e31816e2ea3. J Thorac Oncol. 2008. PMID: 18448999 Free article.

10

Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results.

Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y, Tabata M, Tanimoto M. Oze I, et al. Among authors: hotta k. PLoS One. 2009 Nov 13;4(11):e7835. doi: 10.1371/journal.pone.0007835. PLoS One. 2009. PMID: 19915681 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,494 results

Search Page